CoChat

Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

Di Tacchio, Mariangela, Macas, Jadranka, Weissenberger, Jakob, Sommer, Kathleen, Bähr, Oliver, Steinbach, Joachim P., Senft, Christian, Seifert, Volker, Glas, Martin, Herrlinger, Ulrich, Krex, Dietmar, Meinhardt, Matthias, Weyerbrock, Astrid, Timmer, Marco, Goldbrunner, Roland, Deckert, Martina, Scheel, Andreas H., Büttner, Reinhard, Grauer, Oliver M., Schittenhelm, Jens, Tabatabai, Ghazaleh, Harter, Patrick N., Günther, Stefan, Devraj, Kavi, Plate, Karl H., Reiss, Yvonne · 2019 · Cancer Immunology Research
Cited by 104

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Glioblastoma (GBM) is a non-T-cell–inflamed cancer characterized by an immunosuppressive microenvironment that impedes dendritic cell maturation and T-cell cytotoxicity. Proangiogenic cytokines such as VEGF and angiopoietin-2 (Ang-2) have high expression in glioblastoma in a cell-specific manner and not only drive tumor angiogenesis and vascular permeability but also negatively regulate T-lymphocyte and innate immune cell responses. Consequently, the alleviation of immunosuppression might be a prerequisite for successful immune checkpoint therapy in GBM. We here combined antiangiogenic and immune checkpoint therapy and demonstrated improved therapeutic efficacy in syngeneic, orthotopic GBM models. We observed that blockade of VEGF, Ang-2, and programmed cell death protein-1 (PD-1) significantly extended survival compared with vascular targeting alone. In the GBM microenvironment, triple therapy increased the numbers of CTLs, which inversely correlated with myeloid-derived suppressor cells and regulatory T cells. Transcriptome analysis of GBM microvessels indicated a global vascular normalization that was highest after triple therapy. Our results propose a rationale to overcome tumor immunosuppression and the current limitations of VEGF monotherapy by integrating the synergistic effects of VEGF/Ang-2 and PD-1 blockade to reinforce antitumor immunity through a normalized vasculature.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-18-0865

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 104

Metadata

Authors
Di Tacchio, M., Macas, J., Weissenberger, J., Sommer, K., Bähr, O., Steinbach, J. P., Senft, C., Seifert, V., Glas, M., Herrlinger, U., Krex, D., Meinhardt, M., Weyerbrock, A., Timmer, M., Goldbrunner, R., Deckert, M., Scheel, A. H., Büttner, R., Grauer, O. M., Schittenhelm, J., Tabatabai, G., Harter, P. N., Günther, S., Devraj, K., Plate, K. H., & Reiss, Y.
Venue
Cancer Immunology Research
Published
2019-12-01
Volume
7
Issue
12
Pages
1910-1927
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2979395814
Cited by
104
References
21
FWCI
4.72
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0865
The paper
Di Tacchio, M., Macas, J., Weissenberger, J., Sommer, K., Bähr, O., Steinbach, J. P., Senft, C., Seifert, V., Glas, M., Herrlinger, U., Krex, D., Meinhardt, M., Weyerbrock, A., Timmer, M., Goldbrunner, R., Deckert, M., Scheel, A. H., Büttner, R., Grauer, O. M., . . . Reiss, Y. (2019). Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0865

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.